Dr. Marina Dimitraki, MD, MSc, MHA, PhD, EFOG-EBCOG, Obstetrician-Gynecologist, Assisted Reproduction Specialist at Embryolab and Associate of the European Organization of Reproductive Medicine, ESHRE / EBCOG informs us about and in vitro fertilization.

Luteinizing Hormone (LH) is the key hormone in all three phases of the menstrual cycle. It has a direct correlation with
• the follicle recruitment
• the follicular development and function,
• the mechanisms concerning the final follicular maturation
• the overall endometrial function.

The addition of LH to the ovarian stimulation protocol seems to have a positive effect on the IVF treatment. According to clinical studies, its effectiveness is even greater when applied to
√ women 35-39 years old,
√ women who did not respond positively and according to their prognosis at a previous treatment,
√ women with low ovarian reserve.

We look forward to more researches on the benefits of adding LH to assisted reproductive therapies and to other important groups, such as women with recurrent implantation failures, as well as women with high ovarian reserve who are more likely to present ovarian
hyperstimulation.